Pembrolizumab trial shows promising responses in cutaneous lymphoma

Pembrolizumab trial shows promising responses in cutaneous lymphoma

User Photo
VJHemOnc

2 years
117 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Khodadoust discusses the CITN-10 trial (NCT02243579), which investigated the use of pembrolizumab in relapsed/refractory mycosis fungoides or Sézary syndrome. He highlights the patient response rates and a uniquesideeffect that was observed in the Sézary population.
Up Next Autoplay
>